1319 related articles for article (PubMed ID: 2846630)
21. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
[TBL] [Abstract][Full Text] [Related]
22. Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation.
Cameron ST; Critchley HO; Buckley CH; Kelly RW; Baird DT
Fertil Steril; 1997 Jun; 67(6):1046-53. PubMed ID: 9176442
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
Heikinheimo O; Gordon K; Williams RF; Hodgen GD
Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
[TBL] [Abstract][Full Text] [Related]
24. The effects of progesterone receptor blockade in the luteal phase of normal fertile women.
Li TC; Dockery P; Thomas P; Rogers AW; Lenton EA; Cooke ID
Fertil Steril; 1988 Nov; 50(5):732-42. PubMed ID: 3181485
[TBL] [Abstract][Full Text] [Related]
25. The prediction and/or detection of ovulation by means of urinary steroid assays.
Cekan SZ; Beksac MS; Wang E; Shi S; Masironi B; Landgren BM; Diczfalusy E
Contraception; 1986 Apr; 33(4):327-45. PubMed ID: 3731775
[TBL] [Abstract][Full Text] [Related]
26. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth.
Cameron ST; Thong KJ; Baird DT
Clin Endocrinol (Oxf); 1995 Oct; 43(4):407-14. PubMed ID: 7586613
[TBL] [Abstract][Full Text] [Related]
27. Pituitary, ovarian and endometrial effects of progesterone released prematurely during the proliferative phase.
Shumin X; Johannisson E; Landgren BM; Diczfalusy E
Contraception; 1983 Feb; 27(2):177-93. PubMed ID: 6851555
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical staining of von Willebrand factor in endometrium of women during the first year of Norplant implants use.
Au CL; Affandi B; Rogers PA
Contraception; 1994 Nov; 50(5):477-89. PubMed ID: 7859456
[TBL] [Abstract][Full Text] [Related]
29. The use of anti-progesterones as a medical IUD.
Nieman LK; Loriaux DL
Baillieres Clin Obstet Gynaecol; 1988 Sep; 2(3):609-16. PubMed ID: 3233821
[TBL] [Abstract][Full Text] [Related]
30. Effect of post-coital contraceptive methods on the endometrium and the menstrual cycle.
Swahn ML; Westlund P; Johannisson E; Bygdeman M
Acta Obstet Gynecol Scand; 1996 Sep; 75(8):738-44. PubMed ID: 8906009
[TBL] [Abstract][Full Text] [Related]
31. The concentrations of urinary oestrone-3-glucuronide, LH and pregnanediol-3alpha-glucuronide as indices of ovarian function.
Collins WP; Collins PO; Kilpatrick MJ; Manning PA; Pike JM; Tyler JP
Acta Endocrinol (Copenh); 1979 Feb; 90(2):336-48. PubMed ID: 419920
[TBL] [Abstract][Full Text] [Related]
32. Direct radioimmunoassay of urinary estrogen and pregnanediol glucuronides during the menstrual cycle.
Stanczyk FZ; Miyakawa I; Goebelsmann U
Am J Obstet Gynecol; 1980 Jun; 137(4):443-50. PubMed ID: 7386528
[TBL] [Abstract][Full Text] [Related]
33. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
[TBL] [Abstract][Full Text] [Related]
34. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
[TBL] [Abstract][Full Text] [Related]
35. Effects of long-term low-dose mifepristone on reproductive function in women.
Croxatto HB; Kovács L; Massai R; Resch BA; Fuentealba B; Salvatierra AM; Croxatto HD; Zalányi S; Viski S; Krenács L
Hum Reprod; 1998 Apr; 13(4):793-8. PubMed ID: 9619526
[TBL] [Abstract][Full Text] [Related]
36. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle.
Croxatto HB; Salvatierra AM; Croxatto HD; Fuentealba B
Hum Reprod; 1993 Feb; 8(2):201-7. PubMed ID: 8473419
[TBL] [Abstract][Full Text] [Related]
37. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J; Schmidt-Gollwitzer M
Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
[TBL] [Abstract][Full Text] [Related]
38. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
Barbosa I; Coutinho E; Hirsch C; Ladipo O; Olsson SE; Ulmsten U
Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629
[TBL] [Abstract][Full Text] [Related]
39. Vascular changes in the human endometrium following the administration of the progesterone antagonist RU 486.
Johannisson E; Oberholzer M; Swahn ML; Bygdeman M
Contraception; 1989 Jan; 39(1):103-17. PubMed ID: 2910645
[TBL] [Abstract][Full Text] [Related]
40. Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach.
Lemay A; Jean C; Faure N
Fertil Steril; 1987 Nov; 48(5):775-82. PubMed ID: 2959569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
